What's in China Academy of Chinese Medical Sciences's pipeline?

China Academy of Chinese Medical Sciences has 21 drugs in our index: 20 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with China Academy of Chinese Medical Sciences's portfolio?

Top competitors by shared drug class: Dongzhimen Hospital, Beijing, The First Affiliated Hospital of Guangzhou Medical University, Daiichi Sankyo Co., Ltd., Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Genuine Research Center, Egypt.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/china-academy-of-chinese-medical-sciences.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

China Academy of Chinese Medical Sciences — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

China Academy of Chinese Medical Sciences pipeline: 20 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

20 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
Fufangshuanghua granule	Fufangshuanghua granule	marketed
Sanjin tablets simulants	Sanjin tablets simulants	marketed	Traditional Chinese medicine	Cardiovascular / Hematology
Anerning particle	Anerning particle	marketed
Anshen Buxin Liuwei Pill	Anshen Buxin Liuwei Pill	marketed
amoxil capsule simulator	amoxil capsule simulator	marketed
Sanjin tablets	Sanjin tablets	marketed
Kangfu Anti-inflammatory Suppository	Kangfu Anti-inflammatory Suppository	marketed
Reduning injection	Reduning injection	marketed
Normal-dose Wenxin Granules	Normal-dose Wenxin Granules	marketed
Reyanning mixture	Reyanning mixture	marketed
Xuezhikang capsule	Xuezhikang capsule	marketed	Herbal lipid-lowering agent; statin-containing traditional Chinese medicine	Cardiovascular
Twice Normal-dose Wenxin Granules	Twice Normal-dose Wenxin Granules	marketed	Traditional Chinese medicine herbal formulation	Cardiovascular

Therapeutic area mix

Cardiovascular · 3
Cardiovascular / Hematology · 1
Gynecology · 1
Immunology / Traditional Medicine · 1
Infectious Disease · 1
Infectious Disease / Virology · 1
Other · 1
Pain Management / Cardiovascular · 1
Respiratory/Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dongzhimen Hospital, Beijing · 3 shared drug classes
The First Affiliated Hospital of Guangzhou Medical University · 2 shared drug classes
Daiichi Sankyo Co., Ltd. · 1 shared drug class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
Genuine Research Center, Egypt · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Dalian Zhen-Ao Bio-Tech Co., Ltd. · 1 shared drug class
Cooperative Study Group A for Hematology · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for China Academy of Chinese Medical Sciences:

Cite this brief

Drug Landscape (2026). China Academy of Chinese Medical Sciences — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/china-academy-of-chinese-medical-sciences. Accessed 2026-05-18.